216 related articles for article (PubMed ID: 32694521)
1. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target.
Yu JJ; Zhou DD; Yang XX; Cui B; Tan FW; Wang J; Li K; Shang S; Zhang C; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Huang B; Hua F; Hu ZW
Nat Commun; 2020 Jul; 11(1):3660. PubMed ID: 32694521
[TBL] [Abstract][Full Text] [Related]
2. PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target.
Singh S; Yeat NY; Wang YT; Lin SY; Kuo IY; Wu KP; Wang WJ; Wang WC; Su WC; Wang YC; Chen RH
Cell Death Dis; 2023 Oct; 14(10):671. PubMed ID: 37821451
[TBL] [Abstract][Full Text] [Related]
3. JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation.
Shen J; Liu G; Qi H; Xiang X; Shao J
Cell Death Dis; 2023 Oct; 14(10):657. PubMed ID: 37813845
[TBL] [Abstract][Full Text] [Related]
4. Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Li J; Yan L; Luo J; Tong L; Gao Y; Feng W; Wang F; Cui W; Li S; Sun Z
Biomed Pharmacother; 2021 Jan; 133():110965. PubMed ID: 33166766
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer.
Wang K; Zhou H
Drug Dev Res; 2021 May; 82(3):422-429. PubMed ID: 33231319
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophage-derived transforming growth factor-β promotes colorectal cancer progression through HIF1-TRIB3 signaling.
Liu C; Zhang W; Wang J; Si T; Xing W
Cancer Sci; 2021 Oct; 112(10):4198-4207. PubMed ID: 34375482
[TBL] [Abstract][Full Text] [Related]
7. TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4α stability.
Xiao MC; Jiang N; Chen LL; Liu F; Liu SQ; Ding CH; Wu SH; Wang KQ; Luo YY; Peng Y; Yan FZ; Zhang X; Qian H; Xie WF
J Hepatol; 2024 May; 80(5):778-791. PubMed ID: 38237865
[TBL] [Abstract][Full Text] [Related]
8. TRIB3 promotes malignancy of head and neck squamous cell carcinoma via inhibiting ferroptosis.
Chen L; Lin W; Zhang H; Geng S; Le Z; Wan F; Huang Q; Chen H; Liu X; Lu JJ; Kong L
Cell Death Dis; 2024 Mar; 15(3):178. PubMed ID: 38429254
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations.
Vartak R; Deore B; Sanhueza CA; Patel K
Int J Biol Macromol; 2023 Dec; 252():126413. PubMed ID: 37598823
[TBL] [Abstract][Full Text] [Related]
10. TRIB3 promotes the progression of renal cell carcinoma by upregulating the lipid droplet-associated protein PLIN2.
Li J; Zhang Q; Guan Y; Liao D; Chen H; Xiong H; Sheng Y; Chen X; Pang J
Cell Death Dis; 2024 Apr; 15(4):240. PubMed ID: 38561354
[TBL] [Abstract][Full Text] [Related]
11. Integration of dietary nutrition and TRIB3 action into diabetes mellitus.
Lu G; Li J; Gao T; Liu Q; Chen O; Zhang X; Xiao M; Guo Y; Wang J; Tang Y; Gu J
Nutr Rev; 2024 Feb; 82(3):361-373. PubMed ID: 37226405
[TBL] [Abstract][Full Text] [Related]
12. Wild-type IDH1 maintains NSCLC stemness and chemoresistance through activation of the serine biosynthetic pathway.
Zhang C; Yu JJ; Yang C; Yuan ZL; Zeng H; Wang JJ; Shang S; Lv XX; Liu XT; Liu J; Xue Q; Cui B; Tan FW; Hua F
Sci Transl Med; 2023 Dec; 15(726):eade4113. PubMed ID: 38091408
[TBL] [Abstract][Full Text] [Related]
13. High glucose contributes to the proliferation and migration of non-small cell lung cancer cells via GAS5-TRIB3 axis.
Ding CZ; Guo XF; Wang GL; Wang HT; Xu GH; Liu YY; Wu ZJ; Chen YH; Wang J; Wang WG
Biosci Rep; 2018 Jan; 38(2):. PubMed ID: 29367413
[TBL] [Abstract][Full Text] [Related]
14. Diverse functions of TRIB3 in cancers and its potential as a therapeutic target.
Lei S; Sun J; Xie Y; Xiao X; He X; Lin S; Zhang H; Huang Z; Wang H; Wu X; Peng H; Liu J
Carcinogenesis; 2024 Jun; ():. PubMed ID: 38902892
[TBL] [Abstract][Full Text] [Related]
15. PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia.
Li K; Wang F; Yang ZN; Cui B; Li PP; Li ZY; Hu ZW; Zhu HH
Theranostics; 2020; 10(22):10326-10340. PubMed ID: 32929351
[TBL] [Abstract][Full Text] [Related]
16. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.
Li K; Wang F; Yang ZN; Zhang TT; Yuan YF; Zhao CX; Yeerjiang Z; Cui B; Hua F; Lv XX; Zhang XW; Yu JJ; Liu SS; Yu JM; Shang S; Xiao Y; Hu ZW
Nat Commun; 2020 Dec; 11(1):6316. PubMed ID: 33298911
[TBL] [Abstract][Full Text] [Related]
17. Alteration of genome folding via contact domain boundary insertion.
Zhang D; Huang P; Sharma M; Keller CA; Giardine B; Zhang H; Gilgenast TG; Phillips-Cremins JE; Hardison RC; Blobel GA
Nat Genet; 2020 Oct; 52(10):1076-1087. PubMed ID: 32868908
[TBL] [Abstract][Full Text] [Related]
18. TRIB3 facilitates glioblastoma progression via restraining autophagy.
Tang Z; Chen H; Zhong D; Wei W; Liu L; Duan Q; Han B; Li G
Aging (Albany NY); 2020 Nov; 12(24):25020-25034. PubMed ID: 33203798
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway.
Wang S; Wang C; Li X; Hu Y; Gou R; Guo Q; Nie X; Liu J; Zhu L; Lin B
Cancer Cell Int; 2020; 20():418. PubMed ID: 32874132
[TBL] [Abstract][Full Text] [Related]
20. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
